Ariceum Therapeutics to Present New Findings on Macrocyclic Peptide Radioligands for Tumor Therapy at AACR Annual Meeting

Author:

Berlin-based biotech company Ariceum Therapeutics has announced that it will be presenting new findings on the discovery of novel macrocyclic peptide radioligands for tumor therapy at this year’s American Association for Cancer Research (AACR) Annual Meeting. The research collaboration with UCB, a global pharmaceutical company, explores the use of UCB’s mRNA-display technology platform, ExtremeDiversity™, to select and characterize macrocyclic peptides against an undisclosed target.

Macrocyclic peptides are powerful ligands for radioligand therapeutics (RLT), which aim to selectively deliver radioisotopes to cancer tissues while minimizing damage to surrounding healthy tissues. The new data emphasizes the potential of UCB’s mRNA display platform for rapid and efficient discovery of highly specific macrocyclic peptides with optimal binding properties suitable for RLT.

Ariceum’s Chief Executive Officer, Manfred Rüdiger, expressed excitement about presenting these findings, stating that they have positive implications for the future of precision cancer therapy. The AACR Annual Meeting is viewed as the ideal platform for sharing such groundbreaking research.

The poster presentation, titled “Discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display,” will be presented by Anika Jaekel, Senior Director and Head of Translational Biology and Non-Clinical Pharmacology at Ariceum Therapeutics. The presentation is scheduled for Tuesday, April 9, 2024, from 1:30 PM to 5:00 PM PDT in Poster Section 29.

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain hard-to-treat cancers. Their lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“Satoreotide”), is being developed for the combined diagnosis and targeted radionuclide treatment of neuroendocrine tumors and aggressive cancers. The company is also developing a radiolabelled PARP-inhibitor (ATT001).

Ariceum Therapeutics operates in the biotech industry, specifically focusing on the diagnosis and precision treatment of certain hard-to-treat cancers. The company is in the clinical stage and is dedicated to developing radiopharmaceutical products for targeted radionuclide treatment.

One of Ariceum’s main products is 177Lu-satoreotide tetraxetan, also known as “Satoreotide.” This targeted systemic radiopharmaceutical product is being developed for the combined diagnosis and treatment of neuroendocrine tumors and aggressive cancers. The company is also working on the development of a radiolabelled PARP-inhibitor called ATT001.

The field of radiopharmaceuticals is a growing industry, with a focus on utilizing radioisotopes to deliver targeted therapy to cancer tissues while minimizing damage to healthy tissues. This approach, known as radioligand therapy (RLT), has the potential to revolutionize cancer treatment by providing more precise and effective therapies. The use of macrocyclic peptides as powerful ligands for RLT is an emerging area of research, and Ariceum’s collaboration with UCB highlights the importance of this approach.

The partnership with UCB involves the use of UCB’s mRNA-display technology platform, ExtremeDiversity™, to select and characterize macrocyclic peptides against an undisclosed target. This technology enables rapid and efficient discovery of highly specific macrocyclic peptides with optimal binding properties for RLT.

The presentation of Ariceum’s findings at the AACR Annual Meeting demonstrates the significance of their research in the field of precision cancer therapy. The AACR Annual Meeting is a renowned platform for sharing groundbreaking research in cancer science and attracts professionals from various sectors of the industry.

For more information about Ariceum Therapeutics and their work in the field of radiopharmaceuticals, visit their website: Ariceum Therapeutics.